<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770315</url>
  </required_header>
  <id_info>
    <org_study_id>P05234</org_study_id>
    <secondary_id>3810249</secondary_id>
    <secondary_id>2008-003864-20</secondary_id>
    <secondary_id>MK-3641-002</secondary_id>
    <nct_id>NCT00770315</nct_id>
  </id_info>
  <brief_title>Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH
      39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced
      rhinoconjunctivitis over a one-year period. It is expected that ragweed allergic participants
      on one of the active arms of the trial will have decreased allergic rhinoconjunctivitis
      symptoms and require less allergy rescue medications during ragweed pollen season.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)</measure>
    <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
    <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS</measure>
    <time_frame>Approximately 5 weeks</time_frame>
    <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Rhinoconjunctivitis DSS for the Peak RS</measure>
    <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
    <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Rhinoconjunctivitis DSS for the Entire RS</measure>
    <time_frame>Approximately 5 weeks</time_frame>
    <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Rhinoconjunctivitis DMS for the Peak RS</measure>
    <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
    <description>Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">784</enrollment>
  <condition>Rhinitis, Allergic</condition>
  <condition>Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>SCH 39641 1.5 Amb a 1-U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 39641 6 Amb a 1-U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCH 39641 12 Amb a 1-U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ambrosia artemisiifolia allergen extract (Amb a 1-U)</intervention_name>
    <description>Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.</description>
    <arm_group_label>SCH 39641 1.5 Amb a 1-U</arm_group_label>
    <arm_group_label>SCH 39641 6 Amb a 1-U</arm_group_label>
    <arm_group_label>SCH 39641 12 Amb a 1-U</arm_group_label>
    <other_name>SCH 39641</other_name>
    <other_name>MK-3641</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a clinical history of significant ragweed-induced allergic
             rhinoconjunctivitis of at least 2 years duration, with or without asthma and have
             received treatment during the previous ragweed season (RS).

          -  Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening
             Visit.

          -  Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia
             at Screening Visit.

          -  Must have an forced expiratory volume in one second (FEV1) of at least 70% of
             predicted at Screening Visit.

          -  Safety laboratory tests and vital signs conducted at the Screening Visit must be
             within normal limits or clinically acceptable to the investigator/sponsor.

          -  Must be willing to give written informed consent and be able to adhere to dose and
             visit schedules.

          -  Female participants of childbearing potential must be using a medically acceptable and
             adequate form of birth control. These include: hormonal contraceptives as prescribed
             by a physician (oral, hormonal vaginal ring, hormonal implant or depot injectable);
             medically prescribed intra-uterine device; medically prescribed topically-applied
             transdermal contraceptive patch; double-barrier method (eg, condom in combination with
             a spermicide).

          -  Female participants of childbearing potential should be counseled in the appropriate
             use of birth control while in the study. Female participants who are not currently
             sexually active must and consent to use one of the above-mentioned methods if she
             becomes sexually active during the study.

          -  Female participants of childbearing potential must have a negative urine pregnancy
             test at Screening Visit. Women who have been surgically sterilized or at least 1 year
             postmenopausal are not considered to be of childbearing potential.

        Exclusion Criteria:

          -  Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having
             received regular medication, due to another during or potentially overlapping the RS.

          -  Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma
             due to an allergen to which the participant is regularly exposed.

          -  Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit
             (except steroids for allergic and asthma symptoms).

          -  Clinical history of severe asthma.

          -  Asthma requiring medium or high dose inhaled corticosteroids (ICS).

          -  History of anaphylaxis with cardiorespiratory symptoms.

          -  History of chronic urticaria and angioedema.

          -  Clinical history of chronic sinusitis 2 years prior to the Screening Visit.

          -  Current severe atopic dermatitis.

          -  Breast-feeding, pregnancy, or intending to become pregnant.

          -  Had previous treatment by immunotherapy with ragweed allergen or any other allergen 5
             years prior to Screening Visit.

          -  History of allergy, hypersensitivity or intolerance to the ingredients of the
             investigational medicinal products (except for Ambrosia artemisiifolia), rescue
             medications, or self-injectable epinephrine.

          -  Any clinically significant condition or situation, other than the condition being
             studied that, in the opinion of the investigator, would interfere with the study
             evaluations or optimal participation in the study.

          -  Use of any investigational drugs within 30 days of Screening Visit.

          -  Participation in any other clinical study.

          -  Being a family member of the study staff.

          -  Inability to meet medication washout requirements.

          -  Unlikely to be able to complete the trial, or likely to travel for an extended time
             during the RS.

          -  Clinically significant abnormal vital sign or lab value.

          -  Participation in this same study at another site.

          -  Randomized into this study more than once.

          -  Inability to or will not comply with the use of self-injectable epinephrine.

          -  Greater risk of developing adverse reactions after epinephrine administration.

          -  History of self-injectable epinephrine use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Creticos PS, Maloney J, Bernstein DI, Casale T, Kaur A, Fisher R, Liu N, Murphy K, Nékám K, Nolte H. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013 May;131(5):1342-9.e6. doi: 10.1016/j.jaci.2013.03.019.</citation>
    <PMID>23622121</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <results_first_submitted>April 25, 2014</results_first_submitted>
  <results_first_submitted_qc>June 2, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2014</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SCH 39641 1.5 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Participants receive placebo matching Ambrosia artemisiifolia allergan extract rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="194"/>
                <participants group_id="P4" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="152"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Protocol</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCH 39641 1.5 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Participants receive placebo matching Ambrosia artemisiifolia allergan extract rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="197"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="194"/>
            <count group_id="B4" value="198"/>
            <count group_id="B5" value="784"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="8.83"/>
                    <measurement group_id="B2" value="36.9" spread="8.80"/>
                    <measurement group_id="B3" value="35.6" spread="8.75"/>
                    <measurement group_id="B4" value="36.7" spread="8.54"/>
                    <measurement group_id="B5" value="36.4" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)</title>
        <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
        <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
        <population>The Full Analysis Set (FAS) population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 39641 1.5 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)</title>
          <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
          <population>The Full Analysis Set (FAS) population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="0.517" lower_limit="-1.98" upper_limit="0.45"/>
                    <measurement group_id="O2" value="6.88" spread="0.526" lower_limit="-2.80" upper_limit="-0.36"/>
                    <measurement group_id="O3" value="6.41" spread="0.534" lower_limit="-3.30" upper_limit="-0.79"/>
                    <measurement group_id="O4" value="8.46" spread="0.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2192</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.80</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.30</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS</title>
        <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
        <time_frame>Approximately 5 weeks</time_frame>
        <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 39641 1.5 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Combined Rhinoconjunctivitis DSS and DMS Over the Entire RS</title>
          <description>The total combined score is a composite endpoint that combines the rhinoconjuntivitis DSS and the rhinoconjunctivitis DMS. The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Rhinoconjunctivitis DMS was based on use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. The sum of the rhinoconjunctivitis DSS+DMS could range from 0 to 54, with a lower score indicating less rhinoconjuntivitis symptoms and medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
          <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="0.432" lower_limit="-1.88" upper_limit="0.13"/>
                    <measurement group_id="O2" value="5.81" spread="0.433" lower_limit="-2.29" upper_limit="-0.28"/>
                    <measurement group_id="O3" value="5.18" spread="0.439" lower_limit="-2.95" upper_limit="-0.88"/>
                    <measurement group_id="O4" value="7.09" spread="0.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0878</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.88</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.29</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.95</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinoconjunctivitis DSS for the Peak RS</title>
        <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
        <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
        <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 39641 1.5 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinoconjunctivitis DSS for the Peak RS</title>
          <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
          <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="0.301" lower_limit="-0.96" upper_limit="0.45"/>
                    <measurement group_id="O2" value="4.87" spread="0.306" lower_limit="-1.21" upper_limit="0.21"/>
                    <measurement group_id="O3" value="4.43" spread="0.311" lower_limit="-1.67" upper_limit="-0.21"/>
                    <measurement group_id="O4" value="5.37" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4781</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1695</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.67</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinoconjunctivitis DSS for the Entire RS</title>
        <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
        <time_frame>Approximately 5 weeks</time_frame>
        <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 39641 1.5 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinoconjunctivitis DSS for the Entire RS</title>
          <description>The rhinoconjunctivitis DSS consisted of a total of 6 symptoms (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes and watery eyes) that were measured on a scale of 0 to 3 (0=no symptoms, 3=severe symptoms; score range: 0-18), with a lower score indicating less rhinoconjunctivitis symptoms. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
          <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="0.255" lower_limit="-0.93" upper_limit="0.25"/>
                    <measurement group_id="O2" value="4.19" spread="0.256" lower_limit="-0.99" upper_limit="0.20"/>
                    <measurement group_id="O3" value="3.62" spread="0.259" lower_limit="-1.57" upper_limit="-0.35"/>
                    <measurement group_id="O4" value="4.58" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2622</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1914</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinoconjunctivitis DMS for the Peak RS</title>
        <description>Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
        <time_frame>The 15-day period during the ragweed season with the highest moving pollen average</time_frame>
        <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>SCH 39641 1.5 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>SCH 39641 6 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>SCH 39641 12 Amb a 1-U</title>
            <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinoconjunctivitis DMS for the Peak RS</title>
          <description>Rhinoconjunctivitis DMS was based on participant use of specific study-provided rescue medication, with different rescue medications being assigned different scores/dose unit (score range: 0-36), with a lower score indicating less rhinconjunctivitis medication use. Raw means were converted to adjusted means using an ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects.</description>
          <population>The FAS population consisted of all randomized participants who took at least one dose of study medication and had at least one post-randomization efficacy measurement.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="0.322" lower_limit="-1.26" upper_limit="0.25"/>
                    <measurement group_id="O2" value="2.01" spread="0.328" lower_limit="-1.84" upper_limit="-0.32"/>
                    <measurement group_id="O3" value="1.99" spread="0.333" lower_limit="-1.89" upper_limit="-0.32"/>
                    <measurement group_id="O4" value="3.09" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1900</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.26</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.89</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
            <estimate_desc>ANOVA model with baseline asthmatic condition, pollen region and treatment group as fixed effects</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 53 weeks</time_frame>
      <desc>The population consisted of all randomized participants who took at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>SCH 39641 1.5 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>SCH 39641 6 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="E3">
          <title>SCH 39641 12 Amb a 1-U</title>
          <description>Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Participants receive placebo matching Ambrosia artemisiifolia allergan extract rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Pneumonia chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="196"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="195"/>
                <counts group_id="E3" events="26" subjects_affected="25" subjects_at_risk="194"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E2" events="37" subjects_affected="29" subjects_at_risk="195"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E3" events="14" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="195"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Tongue pruritus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E3" events="21" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E4" events="14" subjects_affected="12" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="31" subjects_at_risk="196"/>
                <counts group_id="E2" events="35" subjects_affected="28" subjects_at_risk="195"/>
                <counts group_id="E3" events="42" subjects_affected="33" subjects_at_risk="194"/>
                <counts group_id="E4" events="45" subjects_affected="35" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="196"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="195"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="195"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="33" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="195"/>
                <counts group_id="E3" events="49" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E4" events="34" subjects_affected="20" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="194"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="195"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="198"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="196"/>
                <counts group_id="E2" events="46" subjects_affected="42" subjects_at_risk="195"/>
                <counts group_id="E3" events="45" subjects_affected="41" subjects_at_risk="194"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="198"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

